Study guide

14.3 Seminal Fluid and Amniotic Fluid Analysis

Philippine Medical Technologists Licensure Examination MTLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety

1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards

2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function

2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice

3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology

3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology

4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety

4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria

5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology

6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology

6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods

7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods

7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control

8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders

8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry

9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders

9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures

11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions

11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin

12 Chapter 12: Clinical Serology and Immunology

12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology

13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control

14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens

14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens

15 Chapter 15: Histopathologic Techniques and Cytotechnology

15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records

16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics

16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics

14.3 Seminal Fluid and Amniotic Fluid Analysis

Key Takeaways Explain This Topic AI

Seminal fluid analysis follows standardized WHO 6th Edition reference standards (volume ≥ 1.4 mL, concentration ≥ 16 × 10^6/mL, total motility ≥ 42%, progressive motility ≥ 30%, normal morphology ≥ 4%, vitality ≥ 54%), requiring strictly 2 to 7 days of sexual abstinence.

The eosin-nigrosin viability test distinguishes true necrozoospermia (dead sperm stained red) from living immotile sperm (viable unstained white sperm displaying structural ciliary defects, as in Kartagener syndrome).

Amniotic fluid fetal lung maturity is confirmed by a thin-layer chromatography L/S ratio ≥ 2.0, detection of phosphatidylglycerol (PG), and automated lamellar body counts ≥ 50,000/µL, while spectrophotometric Delta A450 on a Liley graph evaluates erythroblastosis fetalis.

Amniotic fluid has a creatinine of about 2 mg/dL or less and ferns on drying, while maternal urine has a creatinine above about 10 mg/dL and does not fern.

Elevated amniotic fluid AFP with a positive acetylcholinesterase band confirms an open neural tube defect.

Last updated: October 2026

Seminal Fluid and Amniotic Fluid Analysis

Seminal fluid (8%) and amniotic fluid (2%) are tested within the Clinical Microscopy blueprint. Semen analysis evaluates male fertility and the success of vasectomy and supports forensic work. Amniotic fluid analysis assesses fetal lung maturity, hemolytic disease, and neural tube defects. Both depend on strict collection and handling rules and on reference limits that changed with the WHO 6th edition (2021) semen manual. Fecal analysis and gastric, duodenal, and respiratory specimens are covered in the next two sections.

1. Seminal Fluid Analysis (WHO 6th Edition Standards)

Seminal fluid (semen) is a complex suspension of spermatozoa suspended in seminal plasma produced sequentially by four distinct anatomical glands of the male reproductive tract.

Glandular Contributions to the Ejaculate

Testes and Epididymides (2% to 5% of total volume): The seminiferous tubules produce spermatozoa under the influence of follicle-stimulating hormone (FSH) and testosterone. Spermatozoa mature, acquire progressive motility, and are stored within the epididymis over a 10 to 14 day transit.

Seminal Vesicles (60% to 70% of total volume): Paired glands that secrete a viscous, yellowish, alkaline fluid rich in fructose (the primary metabolic energy substrate for sperm motility), flavins (responsible for sperm fluorescence under ultraviolet light in forensic investigations), and semenogelin I and II (fibrinogen-like coagulating proteins that form the initial gelatinous seminal coagulum).

Prostate Gland (20% to 30% of total volume): Secretes a milky, slightly acidic fluid (pH ≈ 6.5) containing high concentrations of citric acid, zinc, magnesium, acid phosphatase , and proteolytic enzymes—including prostate-specific antigen (PSA) , a serine protease that hydrolyzes semenogelins to liquefy the coagulated semen within 30 to 60 minutes.

Bulbourethral (Cowper's) and Periurethral (Littre) Glands (< 5% of total volume): Produce clear, highly alkaline, mucoid secretions immediately prior to ejaculation that neutralize residual acidic urine in the penile urethra.

Pre-Analytical Requirements and Specimen Collection

Period of Sexual Abstinence: Strictly 2 to 7 days . Abstinence < 2 days produces falsely low semen volume and sperm count; abstinence > 7 days increases sperm count but decreases motility and increases senescence/morphological anomalies.

Collection Technique: Collected by masturbation directly into a sterile, non-toxic, wide-mouthed plastic or glass container. Ordinary latex condoms containing spermicides (nonoxynol-9) must never be used.

Delivery and Temperature: Delivered to the laboratory within 1 hour of collection, maintained at ambient or body temperature ( 20 to 37°C ).

Completeness of Collection: The initial portion of the ejaculate contains the highest concentration of spermatozoa and prostatic secretions; the terminal portion contains seminal vesicle fluid. Loss of the first portion falsely depresses sperm count, while loss of the terminal portion impairs coagulation and reduces volume.

Macroscopic Examination

Liquefaction: Fresh semen forms a firm coagulum that must liquefy into a homogenous liquid within 30 to 60 minutes at room temperature. Delayed or incomplete liquefaction (> 60 minutes) indicates prostatic deficiency (lack of proteolytic enzymes/PSA).

Viscosity: Assessed following complete liquefaction by drawing fluid into a pipette and observing drop formation. Normal semen falls in discrete, watery drops. High viscosity is present if droplets form a persistent thread or strand > 2.0 cm .

Volume: Normal volume is ≥ 1.4 mL (WHO 6th Edition, 2021; previously 1.5 mL in WHO 5th Edition). Volume < 1.4 mL (hypospermia) suggests retrograde ejaculation, incomplete collection, or ejaculatory duct obstruction.

Appearance: Normal semen is translucent, gray-white, and opalescent. Red-brown discoloration indicates hematospermia (erythrocytes); yellow discoloration indicates flavin accumulation, jaundice, or urine contamination; dense turbidity indicates pyospermia.

pH: Measured within 1 hour using narrow-range pH paper. Normal: ≥ 7.2 (typically 7.2 to 8.0). An acidic pH < 7.0 in an azoospermic specimen indicates bilateral seminal vesicle agenesis or complete ejaculatory duct obstruction.

  • Microscopic Examination ┌─ Sperm Concentration ──► ≥ 16 × 10^6 sperm/mL (Total: ≥ 39 × 10^6)
  • │
  • Microscopic Semen Evaluation ─────┼─ Sperm Motility ───────► Progressive (PR) ≥ 30%, Total (PR+NP) ≥ 42%
  • (WHO 6th Edition Standards) │
  • ├─ Sperm Morphology ─────► Normal Forms ≥ 4.0% (Kruger Strict Criteria)
  • │
  • └─ Sperm Vitality ───────► Viable (Unstained) ≥ 54% (Eosin-Nigrosin)

Sperm Concentration and Total Sperm Count: Determined via Improved Neubauer hemocytometer using a 1:20 dilution in an immobilizing solution (5% NaHCO3 and 1% formalin):

Normal Concentration: ≥ 16 × 10^6 spermatozoa/mL .

Normal Total Count per Ejaculate: ≥ 39 × 10^6 spermatozoa (Volume × Concentration).

Terminology: Oligozoospermia (< 16 × 10^6/mL); Azoospermia (complete absence of sperm in native and centrifuged sediment); Aspermia (complete absence of ejaculate).

Motility: Evaluated at 37°C on a wet prep within 60 minutes, grading at least 200 sperm. The WHO 6th edition (2021) restored four grades:

Rapidly Progressive (grade a): Moving actively forward at ≥ 25 μ m/s \ge 25\ \mu\text{m/s} ≥ 25 μ m/s .

Slowly Progressive (grade b): Moving forward at 5 to < 25 μ m/s 5\text{ to }< 25\ \mu\text{m/s} 5 to < 25 μ m/s .

Non-progressive (grade c): Movement without forward progression ( < 5 μ m/s < 5\ \mu\text{m/s} < 5 μ m/s ), such as small circles or flagellar flagging.

Immotile (grade d): No movement.

Reference Limits: Total motility (a + b + c) ≥ 42% and progressive motility (a + b) ≥ 30% . (The WHO 5th edition used three grades with limits of 40% total and 32% progressive.) Asthenozoospermia denotes motility below threshold.

Morphology (Kruger Strict Criteria): Evaluated on air-dried, fixed smears stained with Papanicolaou or Giemsa. Normal sperm features a smooth oval head (4.0 to 5.0 µm length, 2.5 to 3.5 µm width), an acrosome covering 40% to 70% of the head, a slender midpiece (6 to 8 µm), and an uncoiled tail (40 to 50 µm). Normal morphology threshold: ≥ 4.0% normal oval forms . Teratozoospermia denotes < 4% normal forms.

Sperm Vitality / Viability (Eosin-Nigrosin Dye Exclusion): Indicated whenever progressive motility is < 40%. Living sperm possess intact cell membranes that exclude eosin dye, appearing white (unstained) against a dark nigrosin background. Non-viable (dead) sperm have disrupted membranes that absorb eosin, appearing pink or red .

Normal Threshold: ≥ 54% viable spermatozoa (WHO 6th edition; 58% in the 5th edition).

Clinical Significance: Distinguishes true necrozoospermia (dead sperm taking up red stain) from living immotile sperm (white unstained viable sperm with axonemal dynein arm deficiencies, as in Kartagener syndrome / Primary Ciliary Dyskinesia ).

Round Cells: Normal ejaculate contains < 1.0 × 10^6 round cells/mL. A myeloperoxidase stain differentiates peroxidase-positive leukocytes from peroxidase-negative immature spermatids ( leukocytospermia is defined as > 1.0 × 10^6 WBCs/mL, indicating genital tract infection).

Chemical Markers in Seminal Plasma

Fructose (Resorcinol Test): Boiling semen with resorcinol and concentrated hydrochloric acid produces an orange-red precipitate in the presence of fructose. Absence confirms seminal vesicle agenesis or ejaculatory duct obstruction.

Acid Phosphatase and PSA: Extremely concentrated in prostatic fluid; utilized in forensic medicine to confirm suspected semen in sexual assault investigations.

2. Amniotic Fluid Analysis

Amniotic fluid cushions the developing fetus, maintains constant intrauterine temperature, facilitates musculoskeletal development, and provides metabolic waste clearance. Collected via transabdominal amniocentesis under real-time ultrasound guidance.

Differentiation from Maternal Urine

Accidental bladder puncture during amniocentesis must be ruled out immediately:

Amniotic Fluid: Protein positive, glucose positive, low urea nitrogen (< 30 mg/dL), low creatinine (< 3.5 mg/dL, typically 1.5 to 2.0 mg/dL). Shows ferning (arborization) upon air-drying on a glass slide due to protein-electrolyte crystallization.

Maternal Urine: Protein negative, glucose negative, high urea nitrogen (> 300 mg/dL), and very high creatinine ( > 10 mg/dL , typically 30 to 100 mg/dL). Fern test is negative.

Fetal Lung Maturity (FLM) Testing

Neonatal Respiratory Distress Syndrome (RDS) results from insufficient surfactant production by alveolar type II pneumocytes, causing alveolar collapse at expiration.

Lecithin-to-Sphingomyelin (L/S) Ratio: Analyzed via thin-layer chromatography (TLC). Lecithin (dipalmitoylphosphatidylcholine) is the primary alveolar surfactant that rises sharply around week 35 of gestation. Sphingomyelin serves as an internal control, remaining constant.

L/S Ratio ≥ 2.0: Confirms fetal pulmonary maturity (minimal risk of neonatal RDS upon delivery).

L/S Ratio < 1.5: Severe pulmonary immaturity (high risk of neonatal RDS).

Phosphatidylglycerol (PG): An essential minor phospholipid surfactant that appears at 35–36 weeks. Evaluated by slide agglutination (Amniostat-FLM). PG is NOT affected by blood or meconium contamination , which falsely elevates the L/S ratio. PG testing is critical in diabetic pregnancies where surfactant maturation is delayed.

Lamellar Body Count (LBC): Lamellar bodies are layered phospholipid storage packets of surfactant secreted into alveolar spaces. Because lamellar bodies have a particle volume (about 1.7 to 7.3 fL) that overlaps the platelet size window, they are enumerated directly on the platelet channel of automated hematology cell counters without centrifugation.

LBC ≥ 50,000/µL: Definitively confirms fetal lung maturity.

LBC < 15,000/µL: Indicates pulmonary immaturity.

Foam Stability Index (Shake Test): Equal parts 95% ethanol and amniotic fluid are shaken vigorously for 15 seconds. Persistence of a continuous ring of bubbles at the meniscus after 15 minutes indicates surfactant sufficiency.

Hemolytic Disease of the Fetus and Newborn (Erythroblastosis Fetalis)

Fetal erythrocyte destruction mediated by maternal Rh (anti-D) alloantibodies produces unconjugated bilirubin that accumulates in amniotic fluid. Spectrophotometric absorbance is measured across 350 to 700 nm. The net absorbance peak at 450 nm (ΔA450) above a baseline drawn from 365 nm to 550 nm is plotted against gestational age on the Liley Three-Zone Graph :

Zone I (Low Zone): Unaffected or mildly affected fetus; managed conservatively.

Zone II (Mid Zone): Moderate hemolysis; requires serial amniocentesis.

Zone III (High Zone): Severe fetal hemolysis with impending intrauterine fetal demise; mandates immediate intrauterine blood transfusion or emergent delivery.

Neural Tube Defects (NTD)

Alpha-Fetoprotein (AFP): Major fetal serum glycoprotein. Markedly elevated in amniotic fluid and maternal serum in open neural tube defects (anencephaly, spina bifida) and abdominal wall defects (gastroschisis, omphalocele).

Acetylcholinesterase (AChE): Confirmatory testing performed via polyacrylamide gel electrophoresis; presence of an AChE band confirms open neural tube exposure (neural tissue contains acetylcholinesterase, which is absent in non-neural causes of elevated AFP).

  • 3. Summary Reference Tables
  • Semen Analysis Reference Standards (WHO 6th Edition, 2021)
  • Parameter Lower Reference Limit
  • Semen Volume ≥ 1.4 mL
  • Total Sperm Count ≥ 39 × 10^6 sperm/ejaculate
  • Sperm Concentration ≥ 16 × 10^6 sperm/mL
  • Total Motility (PR + NP) ≥ 42%
  • Progressive Motility (PR) ≥ 30%
  • Vitality / Viability (Dye exclusion) ≥ 54% viable (membrane intact)
  • Normal Morphology (Kruger strict) ≥ 4.0% normal forms
  • pH ≥ 7.2
  • Peroxidase-positive Leukocytes < 1.0 × 10^6/mL
  • Seminal and Amniotic Fluid Diagnostic Summary Matrix

Specimen Diagnostic Test Normal Finding Primary Pathological Finding Clinical Correlation

Seminal Fluid Eosin-Nigrosin Stain ≥ 54% unstained (viable) Red stained (non-viable) vs. unstained immotile Differentiates necrozoospermia from Kartagener syndrome

Seminal Fluid Resorcinol Test Orange-red color (fructose +) Colorless (fructose absent) Seminal vesicle agenesis or ejaculatory duct obstruction

Amniotic Fluid L/S Ratio (TLC) ≥ 2.0 < 1.5 High risk of neonatal Respiratory Distress Syndrome

Amniotic Fluid Lamellar Body Count ≥ 50,000/µL < 15,000/µL Pulmonary immaturity; platelet channel automated count

Amniotic Fluid Spectrophotometric ΔA450 Baseline absorption Peak at 450 nm (Liley Zone III) Severe erythroblastosis fetalis from Rh alloimmunization